Description

How Retatrutide Works
Influences appetite regulation mechanisms
Supports calorie control
Participates in metabolic processes
Studied for fat loss
Influences hormonal hunger signals
Benefits of Retatrutide RetaSlim
Modern triagonal GLP-1 / GIP / GCGR
Innovative approach to weight management
Convenient injection pen format
Precise dosage of 40 mg / 3 ml
Actively researched in the field of metabolism
Who might be interested in Retatrutide
The product attracts the attention of people interested in:

Modern peptides for weight management
Metabolic research
Appetite regulation
Biohacking
Innovative anti-aging approaches
Pharmacological properties of Retatrutide RetaSlim PeptoLabs 40 mg Injector Pen mg
This medication is a ready-to-use injection solution containing 40 mg of the active ingredient. It is housed in a convenient pen, making it easy to use anywhere.

Retatrutide 20/40 mg pen is designed for the treatment of obesity, type 2 diabetes, and possibly other metabolic disorders.

It is a multitarget incretin receptor agonist, meaning it activates three types of receptors simultaneously:

GLP-1 (glucagon-like peptide-1) – reduces appetite, slows gastric emptying, and improves insulin sensitivity.
GIP (glucose-dependent insulinotropic peptide) – regulates insulin secretion and fat metabolism.
Glucagon receptors – participate in the regulation of energy metabolism and help burn fat. The drug mimics the action of natural gastrointestinal hormones that regulate hunger and satiety, blood glucose levels, and fat burning.

Clinical trials have shown very high effectiveness in weight loss—up to 24% of starting weight in 48 weeks in obese individuals.

Like other GLP-1 agonists, retatrutide may cause some side effects, including nausea, vomiting, diarrhea, constipation, and decreased appetite.

Retatrutide may be contraindicated in patients with severe gastrointestinal conditions, cancer risks (especially a history of thyroid tumors), pregnancy and lactation, pancreatitis (history or current), and severe liver or kidney dysfunction.

The drug mimics the action of natural gastrointestinal hormones that regulate hunger and satiety, blood glucose levels, and fat burning.

Clinical trials have demonstrated very high effectiveness in weight loss—up to 24% of initial weight in 48 weeks in obese individuals.

Like other GLP-1 agonists, retatrutide may cause some side effects, including nausea, vomiting, diarrhea, constipation, and decreased appetite.

Retatrutide may be contraindicated in patients with severe gastrointestinal conditions, cancer risks (especially a history of thyroid tumors), pregnancy and lactation, history of pancreatitis, or severe liver or kidney dysfunction. (Retatrutide) Retaslim.

Usage:
Consult your doctor before use. The average weight loss course lasts 36 to 48 weeks. Injections are administered subcutaneously once a week in the upper arm, thigh, or abdomen. You should begin with the minimum dosage, and only if well tolerated should it be gradually increased according to the following schedule:

Weeks 1-4 — 2 mg;
Weeks 5-8 — 4 mg;
Weeks 9-12 — 6 mg;
From week 13 — 8-12 mg.
It is not recommended to exceed the maximum dosage.

20mg pen dosage calculation in clicks:
1 click = 66.7 mcg
15 clicks = 1 mg
38 clicks = 2.5 mg
45 clicks = 3 mg
60 clicks = 4 mg
40mg pen dosage calculation in clicks:
1 click = 0.133 mg
19 clicks = 2.5 mg
23 clicks = 3 mg
38 clicks = 5 mg
Ingredients:
Retatrutide

This product is intended for research purposes only. The information has been collected through numerous studies and analyses conducted over many years and is not intended to diagnose, treat, cure, or prevent any disease.

Retatrutide PeptoLabs 40 mg / 3 ml is a modern, next-generation peptide being studied for weight management, appetite, and metabolic processes.

If you’re interested in innovative weight loss peptides and modern approaches to metabolic regulation, Retatrutide is one of the most promising areas for 2026.